| GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas RG Majzner, S Ramakrishna, KW Yeom, S Patel, H Chinnasamy, ... Nature 603 (7903), 934-941, 2022 | 469 | 2022 |
| CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial JY Spiegel, S Patel, L Muffly, NM Hossain, J Oak, JH Baird, MJ Frank, ... Nature medicine 27 (8), 1419-1431, 2021 | 381 | 2021 |
| Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia S Arcangeli, MC Rotiroti, M Bardelli, L Simonelli, CF Magnani, A Biondi, ... Molecular therapy 25 (8), 1933-1945, 2017 | 163 | 2017 |
| Co-opting signalling molecules enables logic-gated control of CAR T cells AM Tousley, MC Rotiroti, L Labanieh, LW Rysavy, WJ Kim, C Lareau, ... Nature 615 (7952), 507-516, 2023 | 87 | 2023 |
| CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering RG Majzner, MJ Frank, C Mount, A Tousley, DM Kurtz, B Sworder, ... Blood 136, 53-54, 2020 | 43 | 2020 |
| Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1 NW Mabe, M Huang, GN Dalton, G Alexe, DA Schaefer, AC Geraghty, ... Nature cancer 3 (8), 976-993, 2022 | 39 | 2022 |
| Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system MC Rotiroti, C Buracchi, S Arcangeli, S Galimberti, MG Valsecchi, ... Molecular Therapy 28 (9), 1974-1986, 2020 | 39 | 2020 |
| Acute myeloid leukemia targeting by chimeric antigen receptor T cells: bridging the gap from preclinical modeling to human studies MC Rotiroti, S Arcangeli, M Casucci, V Perriello, A Bondanza, A Biondi, ... Human gene therapy 28 (3), 231-241, 2017 | 21 | 2017 |
| Lenalidomide enhances CD23. CAR T cell therapy in chronic lymphocytic leukemia S Tettamanti, MC Rotiroti, GMP Giordano Attianese, S Arcangeli, R Zhang, ... Leukemia & lymphoma 63 (7), 1566-1579, 2022 | 18 | 2022 |
| IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML VM Perriello, MC Rotiroti, I Pisani, S Galimberti, G Alberti, G Pianigiani, ... Blood Advances 7 (12), 2855-2871, 2023 | 11 | 2023 |
| Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use E Gotti, S Tettamanti, S Zaninelli, C Cuofano, I Cattaneo, MC Rotiroti, ... Cytotherapy 24 (3), 334-343, 2022 | 11 | 2022 |
| Unraveling the efficacy and safety profiles of anti-CD123 chimeric antigen receptors (CARs) in a model of acute myeloid leukemia immunotherapy by investigating CAR binding … S Arcangeli, M Bardelli, S Tettamanti, MC Rotiroti, L Simonelli, ... Blood 126 (23), 1359, 2015 | 6 | 2015 |
| Coopting T cell proximal signaling molecules enables Boolean logic-gated CAR T cell control AM Tousley, MC Rotiroti, L Labanieh, LW Rysavy, SP Rietberg, ... bioRxiv, 2022.06. 17.496457, 2022 | 5 | 2022 |
| CD123 and CD33 co-targeting by balanced signaling on CAR-CIK cells reduces potential off-target toxicity while preserving the anti-leukemic activity of acute myeloid leukemia VM Perriello, MC Rotiroti, I Pisani, G Alberti, G Pianigiani, R Rossi, ... Blood 138, 1699, 2021 | 5 | 2021 |
| Balance of anti-CD123 chimeric antigen receptor (CAR) binding affinity and density for the treatment of acute myeloid leukemia S Arcangeli, M Bardelli, MC Rotiroti, L Simonelli, CF Magnani, L Varani, ... Blood 128 (22), 2163, 2016 | 2 | 2016 |
| Tuned IL3-Zetakine coupled to a CD33 costimulatory receptor as a dual CAR for safer and selective targeting of acute myeloid leukemia VM Perriello, MC Rotiroti, I Pisani, S Galimberti, G Alberti, G Pianigiani, ... Blood 140 (Supplement 1), 10237-10238, 2022 | 1 | 2022 |
| Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR) MC Rotiroti, S Arcangeli, C Buracchi, CF Magnani, C Cappuzzello, ... Blood 132, 2201, 2018 | 1 | 2018 |
| Enhancing t cell function through the use of proximal signaling molecules RG Majzner, A Tousley, MC Rotiroti US Patent App. 18/552,478, 2024 | | 2024 |
| Immunotherapy-related cognitive impairment after CAR T cell therapy in mice AC Geraghty, L Acosta-Alvarez, M Rotiroti, S Dutton, MR O’Dea, PJ Woo, ... bioRxiv, 2024 | | 2024 |
| Chimeric antigen receptor (car) signaling molecules for controlled and specific car t cell activity RG Majzner, A Tousley, L Labanieh, CL Mackall, MC Rotiroti US Patent App. 18/547,652, 2024 | | 2024 |
